Literature DB >> 32546380

ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases.

Aline F Fares1, Benjamin H Lok2, Tong Zhang3, Michael Cabanero4, Sally C M Lau1, Tracy Stockley3, Devalben Patel1, Penelope A Bradbury1, Adrian Sacher1, Kazuhiro Yasufuku5, Barbara A Morash3, Peter J B Sabatini3, Lananhn N Nguyen4, Natasha B Leighl1, Ming-Sound Tsao4, Frances A Shepherd1, Geoffrey Liu6, Sebastiao N Martins-Filho4, Prodipto Pal4.   

Abstract

Entities:  

Keywords:  ALK-translocation; Histologic-transformation; Large-cell-neuroendocrine-carcinoma

Mesh：

Substances：

Year:  2020        PMID： 32546380     DOI： 10.1016/j.lungcan.2020.06.005

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  5 in total

1.  Targeting ALK in Neuroendocrine Tumors of the Lung.

Authors:  Dilara Akhoundova; Martina Haberecker; Ralph Fritsch; Sylvia Höller; Michael K Kiessling; Markus Rechsteiner; Jan H Rüschoff; Alessandra Curioni-Fontecedro
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

Review 2.  Histologic transformation in lung cancer: when one door shuts, another opens.

Authors:  Yuki Sato; Go Saito; Daichi Fujimoto
Journal:  Ther Adv Med Oncol       Date:  2022-10-14       Impact factor: 5.485

3.  A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib.

Authors:  Chloe A Lim; Norbert Banyi; Tracy Tucker; Diana N Ionescu; Barbara Melosky
Journal:  Curr Oncol       Date:  2022-02-03       Impact factor: 3.677

Review 4.  ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.

Authors:  Sébastien Gendarme; Olivier Bylicki; Christos Chouaid; Florian Guisier
Journal:  Curr Oncol       Date:  2022-01-28       Impact factor: 3.677

5.  The quantum leap in therapeutics for advanced ALK+ non-small cell lung cancer and pursuit to cure with precision medicine.

Authors:  Malinda Itchins; Nick Pavlakis
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.